Vanguard Group Inc Bio Atla, Inc. Transaction History

Vanguard Group Inc

  • $5.97 Trillion
  • Q2 2025

A detailed history of Vanguard Group Inc transactions in Bio Atla, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,783,148 shares of BCAB stock, worth $659,764. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,783,148
Previous 1,818,002 1.92%
Holding current value
$659,764
Previous $636,000 12.11%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 11, 2025
SELL
$0.27 - $0.56 $9,410 - $19,518
-34,854 Reduced 1.92%
1,783,148 $713,000
Q1 2025

May 09, 2025
SELL
$0.28 - $0.68 $4,052 - $9,842
-14,474 Reduced 0.79%
1,818,002 $636,000
Q4 2024

Feb 11, 2025
SELL
$0.59 - $2.37 $31,137 - $125,079
-52,776 Reduced 2.8%
1,832,476 $1.08 Million
Q2 2024

Aug 13, 2024
SELL
$1.37 - $3.92 $292,885 - $838,037
-213,785 Reduced 10.18%
1,885,252 $2.58 Million
Q1 2024

May 10, 2024
BUY
$1.88 - $3.46 $33,213 - $61,127
17,667 Added 0.85%
2,099,037 $7.22 Million
Q4 2023

Feb 14, 2024
SELL
$1.27 - $3.18 $26,601 - $66,608
-20,946 Reduced 1.0%
2,081,370 $5.12 Million
Q3 2023

Nov 14, 2023
BUY
$1.7 - $3.07 $7,847 - $14,171
4,616 Added 0.22%
2,102,316 $3.57 Million
Q2 2023

Aug 14, 2023
BUY
$2.83 - $3.87 $493,339 - $674,637
174,325 Added 9.06%
2,097,700 $6.29 Million
Q1 2023

May 15, 2023
SELL
$2.3 - $8.25 $17,627 - $63,228
-7,664 Reduced 0.4%
1,923,375 $5.15 Million
Q4 2022

Feb 10, 2023
BUY
$6.29 - $11.01 $3.29 Million - $5.76 Million
522,807 Added 37.13%
1,931,039 $15.9 Million
Q3 2022

Nov 14, 2022
BUY
$2.94 - $11.87 $774,975 - $3.13 Million
263,597 Added 23.03%
1,408,232 $10.8 Million
Q2 2022

Aug 12, 2022
SELL
$2.13 - $5.38 $876,808 - $2.21 Million
-411,647 Reduced 26.45%
1,144,635 $3.26 Million
Q1 2022

May 13, 2022
SELL
$4.38 - $18.78 $3.1 Million - $13.3 Million
-708,372 Reduced 31.28%
1,556,282 $7.78 Million
Q4 2021

Feb 14, 2022
BUY
$19.0 - $30.95 $3.34 Million - $5.44 Million
175,631 Added 8.41%
2,264,654 $44.5 Million
Q3 2021

Nov 12, 2021
BUY
$29.44 - $43.74 $30.7 Million - $45.5 Million
1,041,111 Added 99.35%
2,089,023 $61.5 Million
Q2 2021

Aug 13, 2021
BUY
$38.07 - $56.17 $39.9 Million - $58.9 Million
1,047,912 New
1,047,912 $44.4 Million

Others Institutions Holding BCAB

# of Institutions
41
Shares Held
13.4M
Call Options Held
20.7K
Put Options Held
0
View Full List

About BioAtla, Inc.

BCAB Quotes by TradingView
  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $13.4M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email